Jessica Carmen, Ph.D.

Dr. Carmen brings over 20 years of experience in the cell and gene therapy industry.

Previously, she was Vice President of Business Development for Kincell Bio, a contract development and manufacturing Organization (CDMO) focused on cell therapies. In a consulting capacity, she supported the business development team at Oxford Biomedica, a manufacturer of clinical and commercial viral vectors. She has broad technical knowledge base in cell and gene therapies, with a deep understanding of the manufacturing of these innovative medicines and unique insights into the commercialization of tools and services to support the manufacture of these therapies.

In her prior roles, she has been responsible for out-licensing a non-viral enabling technology for cellular engineering at MaxCyte. She was also instrumental in establishing partnerships with developers of cell-based medicines while expanding the cell therapy contract manufacturing business at Lonza. Additionally, Dr. Carmen played a key role in the establishment of the Standards Coordinating Body for Regenerative Medicines and is currently serving as Vice President of the Board of Directors.

She has been a member of the Science and Technology Committee of the Alliance for Regenerative Medicine and has served on the Commercialization Committee for the International Society of Cellular Therapy. Dr. Carmen earned a Doctorate from the Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science from the University of Florida.